Eli Lilly falls after late-stage data for oral weight-loss drug

** Shares of drugmaker Eli Lilly LLY.N fall 11.6% to $660.53 premarket

** Co reports late-stage data from its oral weight loss drug, orforglipron

** Orforglipron helped overweight or obese patients lose 12.4% of their body weight on average after 72 weeks in a late-stage study -LLY

** Says just over 10% of the high-dose patients dropped out of the trial due to adverse side effects

** Up to last close, stock down 3.3% YTD